Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Perrigo Company plc    PRGO   IE00BGH1M568

PERRIGO COMPANY PLC

(PRGO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Perrigo Company plc
Perrigo Company PLC (Perrigo), formerly Perrigo Company Limited, is an over-the-counter (OTC) consumer goods and specialty pharmaceutical company. The Company's segments include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx) and Specialty Sciences. It manufactures OTC healthcare products and supplies infant formulas for the store brand market. It is also a provider of generic extended topical prescription products. The CHC segment is focused on the sale of OTC store brand products. The BCH segment develops, manufactures, markets and distributes various European OTC brands. The Rx segment develops, manufactures and markets a portfolio of generic and specialty pharmaceutical prescription drugs. The Specialty Sciences segment consists of assets focused on the treatment of multiple sclerosis, specifically in connection with the drug, Tysabri.

Number of employees : 10 600 people.
Sales per Businesses
20172018Delta
USD (in Million)%USD (in Million)%
Consumer Healthcare Americas2,43049.1%2,41251% -0.75%
Consumer Healthcare International1,49130.2%1,49631.6% +0.33%
Prescription Pharmaceuticals969.7019.6%824.2017.4% -15%
Other55.601.1%---
Sales per Regions
20172018Delta
USD (in Million)%USD (in Million)%
United States3,27266.2%3,09865.5% -5.32%
Europe1,31326.6%1,32227.9% +0.66%
All Other Countries330.306.7%285.806% -13.47%
Ireland30.400.6%25.700.5% -15.46%
Managers
NameAgeSinceTitle
Murray Kessler592018President, Chief Executive Officer & Director
Rolf Classon732018Chairman
Ronald Janish-2015Executive VP-Global Operations and Supply Chain
Raymond P. Silcock692019Chief Financial & Accounting Officer
Thomas Farrington612015Chief Information Officer & Executive VP
Grainne Quinn, Dr.492015Chief Medical Officer & Executive Vice President
James E. Dillard-2019Chief Scientific Officer & Executive VP
Donal M. O'Connor682014Independent Director
Geoffrey M. Parker542016Independent Director
Theodore Rapp Samuels642017Independent Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Stock A 1 136,109,593 135,429,003 99.5% 0 0.0% 99.5%
Shareholders
NameEquities%
T. Rowe Price Associates, Inc. (Investment Management) 18,473,951 13.6%
The Vanguard Group, Inc. 15,398,920 11.3%
Fidelity Management & Research Co. 6,295,382 4.63%
SSgA Funds Management, Inc. 6,270,068 4.61%
Starboard Value LP 4,100,000 3.01%
Southeastern Asset Management, Inc. 4,038,200 2.97%
Parnassus Investments 3,685,834 2.71%
Franklin Mutual Advisers LLC 3,499,842 2.57%
BlackRock Fund Advisors 3,453,291 2.54%
Carmignac Gestion SA 3,224,624 2.37%
Holdings
NameEquities%Valuation
Proteostasis Therapeutics, Inc. (PTI) 2,908,0675.69%6,630,393 USD
Company contact information
Perrigo Co. Plc
The Sharp Building
Hogan Place
Dublin 2

Phone : +353.1.709.4000
Web : http://www.perrigo.com
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
PERRIGO COMPANY PLC14.25%8 033
JOHNSON & JOHNSON2.26%392 596
ROCHE HOLDING AG4.44%289 068
MERCK AND COMPANY0.02%231 608
PFIZER3.39%224 187
NOVARTIS0.96%216 654
BRISTOL-MYERS SQUIBB COMPANY3.94%156 404
NOVO NORDISK AS6.96%144 481
AMGEN0.17%143 489
ELI LILLY AND COMPANY6.20%134 015
ASTRAZENECA3.02%133 679
ABBVIE INC.-0.61%130 136
SANOFI2.54%127 703
GLAXOSMITHKLINE3.32%118 266
BAYER AG3.69%82 204
ALLERGAN PLC0.79%63 252
TAKEDA PHARMACEUTICAL COMPANY LIMITED3.26%62 746
JIANGSU HENGRUI MEDICINE CO., LTD.3.59%57 784
CHUGAI PHARMACEUTICAL CO., LTD.6.75%53 051
DAIICHI SANKYO COMPANY, LIMITED2.66%43 185
ASTELLAS PHARMA INC.1.65%31 869
Connections : Perrigo Company plc